Recent Discovery on tRNA Halves in Prostate Cancer

Tiny pieces of genetic material called tRNA halves play a surprising role in fueling prostate cancer growth, according to new research published in PLOS Biology. These molecules form when normal tRNA, short strands of RNA that help build proteins, get split in half inside cells, especially those driven by male hormones like in prostate cancer.

In healthy cells, growth is tightly controlled, much like a car’s brakes preventing it from speeding out of control. One key brake is a protein called p21, which tells cells to pause and not divide too quickly. But in prostate cancer cells sensitive to male hormones, tRNA halves act like thieves that disable this brake: they latch onto a helpful protein (Y-box binding protein 1) that normally protects the p21 blueprint (its mRNA) from breaking down.
​
Without that protection, the p21 blueprint degrades faster, leaving less p21 protein to slow growth. Experiments showed that when these tRNA halves are removed from cancer cells, p21 levels rise, cells get stuck in an early growth phase (G1), and overall tumor cell numbers drop sharply, proving the halves push the cancer forward. The tRNA halves are far more abundant than the p21 blueprint (over 140 times more), so they easily outcompete it for the protective protein, like a crowd shoving someone aside.

This happens mainly in hormone-fueled prostate cancers, where male hormones trigger constant production of these tRNA halves to keep p21 low and cells multiplying. Unlike stress-induced tRNA halves that appear briefly, these stay around to support ongoing tumor growth. The discovery points to tRNA halves as potential markers for these cancers or even targets for new drugs that could restore the p21 brake and slow tumors.

Source.